ClinicalTrials.gg
TerminatedNCT06682299Updated May 12, 2026Results posted

Maintenance TMS in Treatment Resistant Depression

An interventional study of Transmagnetic Stimulation and Electroconvulsive Therapy in Treatment Resistant Depression (TRD), sponsored by Austin Messner. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Austin Messner · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
167th of 181
1 · median 38
Started
2025
with 11 others
No phase
72 of 205
21 open now
Registered
179th of 205
by date

Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 167th largest by enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2025, is one of 72 with no phase, and was the 179th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder.

This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.

Read the detailed description

The clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder.

Patients who choose maintenance TMS will initiate maintenance TMS sessions on day one of the study and continue any currently prescribed pharmacotherapy. Participants will initiate TMS treatment within 1 week of last index ECT treatment. Participants will then follow a schedule of weekly for 4 sessions, every other week for 4 sessions, and monthly for 3 sessions for a total of 11 sessions in 6 months. Investigators will use the TMS paradigm called intermittent theta burst stimulation (iTBS), which was used in the SNT trial(Cole et al., 2022; Cole et al., 2020). At conclusion of the 6 month TMS portion of the study clinical judgement will be used to determine if the patient will return to maintenance ECT treatment. RBANS for assessment of cognition will be completed at the beginning, after 6 months, and at the conclusion of the study as well in both the standard of care and TMS portions of the study.

Those who choose maintenance ECT will transition to maintenance ECT treatments in the hospital as prescribed by their treating inpatient psychiatrists. On initial visit consent will be obtained and baseline cognitive and behavioral scales assessed as follows: Antidepressant treatment history form (ATHF), alcohol use disorder identification test (AUDIT-C), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), quick inventory of depressive symptomology (QIDS), Brief Psychiatric Rating Scale (BPRS), Drug Abuse Screening Test (DAST-10), Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS), standardized assessment of personality abbreviated scale (SAPAS). Patients will then be asked to return at 6 month and 12 month intervals to repeat HDRS, QIDS, RBANS, and CGI scales.

Research data will be collected primarily through self assessment scales including Antidepressant treatment history form (ATHF), alcohol use disorder identification test (AUDIT-C), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), quick inventory of depressive symptomology (QIDS), Brief Psychiatric Rating Scale (BPRS), Drug Abuse Screening Test (DAST-10), Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS), standardized assessment of personality abbreviated scale (SAPAS).

03

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • depression
  • tms
  • ect
  • treatment resistant depression
  • trd
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated for TRD who have achieved remission through an index series of ECT
  • Able to provide
  • Age between 18 and 65 years
  • Deemed appropriate for maintenance TMS by their psychiatrist
  • Right-handed

Exclusion criteria

Exclusion Criteria:

  • History of seizures or a seizure disorder
  • Related neurological disorder, or any other medical condition that would preclude TMS treatment determined by the treatment team.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    TMS

    Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. They will receive TMS in this arm of study for maintenance treatment of their depression and monitored with depressive scales.

    Device: Transmagnetic Stimulation

  • Active comparator
    ECT

    Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. If they elect to continue with maintenance ECT treatments which is the current standard of care, their depressive symptoms and cognitive functioning will be monitored accordingly.

    Device: Electroconvulsive Therapy

Interventions

  • DeviceTransmagnetic Stimulation

    TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).

    Also known as: TMS

  • DeviceElectroconvulsive Therapy

    Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression

    Also known as: ECT

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HDRS)

    One of the most widely used clinician administered depression scales containing 17 items. Scores range from 0 to 54 with 0-7 being normal, 8-16 being mild depression, 17-23 moderate depression and 24 or greater being severe depression. Higher scores equate to more severe depressive symptoms.

    Time frame: Baseline and prior to each procedure for duration of study, up to six months

Secondary outcomes

  1. Change in Quick Inventory of Depressive Symptomatology (QIDS)

    A widely used self-report scale of depression with similar validity to the HDRS that consists of 16 scale items. Scores range from 0 to 27 with 0-5 indicating no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe, and 21 or higher very severe. Higher scores equate to more severe depressive symptoms.

    Time frame: Baseline and prior to each procedure for duration of study, up to six months

  2. Change in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)

    Cognitive screening tool that is individually administered battery to measure cognitive decline or improvement. Scores range from 40 to 160. 69 and below is extremely low, 70-79 borderline, 80-89 low average, 90-109 average, 110-119 high average, 12-129 superior, and 130+ very superior. Higher scores equate to better cognitive functioning.

    Time frame: Baseline on initial presentation, at 6 months, and at 12 months

07

Results

Posted May 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneTranscranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)
Started10
Completed00
Not completed10

Outcome measures

PrimaryChange in Hamilton Depression Rating Scale (HDRS)

One of the most widely used clinician administered depression scales containing 17 items. Scores range from 0 to 54 with 0-7 being normal, 8-16 being mild depression, 17-23 moderate depression and 24 or greater being severe depression. Higher scores equate to more severe depressive symptoms.

Time frame:
Baseline and prior to each procedure for duration of study, up to six months
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryChange in Quick Inventory of Depressive Symptomatology (QIDS)

A widely used self-report scale of depression with similar validity to the HDRS that consists of 16 scale items. Scores range from 0 to 27 with 0-5 indicating no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe, and 21 or higher very severe. Higher scores equate to more severe depressive symptoms.

Time frame:
Baseline and prior to each procedure for duration of study, up to six months
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryChange in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)

Cognitive screening tool that is individually administered battery to measure cognitive decline or improvement. Scores range from 40 to 160. 69 and below is extremely low, 70-79 borderline, 80-89 low average, 90-109 average, 110-119 high average, 12-129 superior, and 130+ very superior. Higher scores equate to better cognitive functioning.

Time frame:
Baseline on initial presentation, at 6 months, and at 12 months

No measurements were reported for this outcome.

Adverse events

Collected over Only 1 participant was enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Transcranial Magnetic Stimulation (TMS)———
Electroconvulsive Therapy (ECT)———

Baseline characteristics

0 participants enrolled in the ECT arm

Age, Categorical
Age, Categorical(Participants)Transcranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)Total
<=18 years000
Between 18 and 65 years000
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Transcranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)Total
Female101
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Transcranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)Total
Hispanic or Latino000
Not Hispanic or Latino101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Transcranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Transcranial Magnetic Stimulation (TMS)Electroconvulsive Therapy (ECT)Total
United States1—1
08

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40509, United States
09

References and documents

Publications

  • Rachid F. Safety and Efficacy of Theta-Burst Stimulation in the Treatment of Psychiatric Disorders: A Review of the Literature. J Nerv Ment Dis. 2017 Nov;205(11):823-839. doi: 10.1097/NMD.0000000000000742. PubMed 29077650 ↗
  • Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. PubMed 19833552 ↗
  • Wilson S, Croarkin PE, Aaronson ST, Carpenter LL, Cochran M, Stultz DJ, Kozel FA. Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS. J Affect Disord. 2022 Jan 1;296:79-88. doi: 10.1016/j.jad.2021.09.040. Epub 2021 Sep 17. PubMed 34592659 ↗
  • Magnezi R, Aminov E, Shmuel D, Dreifuss M, Dannon P. Comparison between neurostimulation techniques repetitive transcranial magnetic stimulation vs electroconvulsive therapy for the treatment of resistant depression: patient preference and cost-effectiveness. Patient Prefer Adherence. 2016 Aug 4;10:1481-7. doi: 10.2147/PPA.S105654. eCollection 2016. PubMed 27536079 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2025, 2 months.

Results were first posted in May 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Apr 17, 2025
Primary completionActual
Jun 26, 2025
CompletionActual
Jun 26, 2025
Results first posted
May 12, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06682299
Lead sponsor
Austin Messner
Responsible party
Austin Messner (Senior Medical Resident, University of Kentucky) — Sponsor-investigator
First posted
Nov 12, 2024
Start date
Apr 17, 2025
Primary completion
Jun 26, 2025
Completion
Jun 26, 2025
Results posted
May 12, 2026
Last update
May 12, 2026

Study contacts

Gopalkumar Rakesh, MD
study director · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion